, a bio/informatics shared resource is still "open for business" - Visit the CDS website


Inhibition of PI3K and MEK: it is all about combinations and biomarkers.

Rexer BN, Ghosh R, Arteaga CL
Clin Cancer Res. 2009 15 (14): 4518-20

PMID: 19584146 · DOI:10.1158/1078-0432.CCR-09-0872

A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

MeSH Terms (17)

Animals Antineoplastic Agents Biomarkers, Tumor Breast Neoplasms Cell Line, Tumor Enzyme Inhibitors Female Humans Mammary Neoplasms, Experimental MAP Kinase Kinase 1 Mice Mice, Inbred Strains Mice, Nude Models, Biological Phosphatidylinositol 3-Kinases Phosphoinositide-3 Kinase Inhibitors Xenograft Model Antitumor Assays

Connections (1)

This publication is referenced by other Labnodes entities:

Links